Skip to main content
SpringerLink
Log in

Role of Hematopoietic Cell Transplantation for Myeloma

  • Chapter
  • First Online:
Neoplastic Diseases of the Blood

  • 2203 Accesses

Abstract

It has been more than 30 years since McElwain and Powles demonstrated the benefits of high-dose melphalan in the treatment of relapse and refractory myeloma. With autologous hematopoietic cell support high-dose melphalan has become the best available strategy to achieve high CR rates and prolong PFS as consolidation of a proteosome inhibitor, immune-modulatory drug, and steroid induction therapy.

However, the best timing of HCT remains an area of active debate and major interest with most ongoing clinical trials showing progression-free survival benefit and some showing survival benefit. Although significant advances have been made in myeloma therapy no major changes have occurred in the setting of high-dose melphalan therapy. In this chapter we review current status and future directions of high-dose therapy for myeloma.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet. 1983;2(8354):822–4.

    Article  CAS  PubMed  Google Scholar 

  2. Selby PJ, McElwain TJ, Nandi AC, et al. Multiple myeloma treated with high dose intravenous melphalan. Br J Haematol. 1987;66(1):55–62.

    Article  CAS  PubMed  Google Scholar 

  3. Barlogie B, Hall R, Zander A, Dicke K, Alexanian R. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood. 1986;67:1298–301.

    CAS  PubMed  Google Scholar 

  4. Barlogie B, Alexanian R, Dicke KA, Zagars G, Spitzer G, Jagannath S, Horwitz L. High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood. 1987;70(3):869–72.

    CAS  PubMed  Google Scholar 

  5. Jagannath S, Barlogie B, Dicke K, Alexanian R, Zagars G, Cheson B, Lemaistre FC, Smallwood L, Pruitt K, Dixon DO. Autologous bone marrow transplantation in multiple myeloma: identification of prognostic factors. Blood. 1990;76(9):1860–6.

    CAS  PubMed  Google Scholar 

  6. Goldschmidt H, Hegenbart U, Wallmeier M, Moos M, Haas R. High-dose chemotherapy in multiple myeloma. Leukemia. 1997;11(Suppl 5):S27–31.

    CAS  PubMed  Google Scholar 

  7. Fermand JP, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood. 1998;92(9):3131–6.

    CAS  PubMed  Google Scholar 

  8. Child JA, Morgan G, Davies F, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348(19):1875–83.

    Article  CAS  PubMed  Google Scholar 

  9. Blade J, Rosiñol L, Sureda A, et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood. 2005;106(12):3755–9.

    Article  CAS  PubMed  Google Scholar 

  10. Fermand JP, Katsahian S, Divine M, et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol. 2005;23(36):9227–33.

    Article  CAS  PubMed  Google Scholar 

  11. Attal M, Harrousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med. 1996;335(2):91–7.

    Article  CAS  PubMed  Google Scholar 

  12. Barlogie B, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood. 1997;89(3):789–93.

    CAS  PubMed  Google Scholar 

  13. Lenhoff S, Hjorth M, Turesson I, et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Blood. 2000;95(1):7–11.

    CAS  PubMed  Google Scholar 

  14. Koreth J, Cutler CS, Djulbegovic B, et al. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant. 2007;13(2):183–96. Review

    Article  CAS  PubMed  Google Scholar 

  15. Alexanian R, et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant. 2001;27(10):1037–43.

    Article  CAS  PubMed  Google Scholar 

  16. Lane SW, Gill D, Mollee PN, Rajkumar SV. Role of VAD in the initial treatment of multiple myeloma. Blood. 2005;106(10):3674; author reply 3674–5. No abstract available.

  17. Wiedewult M and Giralt S: Clinical Hematopoietic Cell Transplantation American Society of Hematology Self Assessment Program 6th Edition.

    Google Scholar 

  18. CIBMTR data.

    Google Scholar 

  19. Shah N, Callander N, Ganguly S, et al. Hematopoietic Stem Cell Transplantation for Multiple myeloma: guidelines from the american society for blood and marrow transplantation. Biol Blood Marrow Transplant. 2015;21:1155–66.

    Article  PubMed  Google Scholar 

  20. Ozaki S, Harada T, Saitoh T, et al. Survival of multiple myeloma patients aged 65–70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network. Acta Haematol. 2014;132:211–9.

    Article  PubMed  Google Scholar 

  21. Bashir Q, Shah N, Parmar S, et al. Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myeloma. Leuk Lymphoma. 2012;53:118–22.

    Article  CAS  PubMed  Google Scholar 

  22. Merz M, Neben K, Raab MS, et al. Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents. Ann Oncol. 2014;25:189–95.

    Article  CAS  PubMed  Google Scholar 

  23. Muchtar E, Dingli D, Kumar S, Buadi FK, et al. Autologous stem cell transplant for multiple myeloma patients 70 years or older. Bone Marrow Transplant. 2016 Nov;51(11):1449–55. https://doi.org/10.1038/bmt.2016.174.

    Article  CAS  PubMed  Google Scholar 

  24. Reece D, Bredeson C, Perez WS, et al. Autologous stem cell transplantation in multiple myeloma patients <60 vs. ≥60 years of age. Bone Marrow Transplant. 2003;32(12):1135–43.

    Article  CAS  PubMed  Google Scholar 

  25. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Saad A, Mahindra A, Zhang MJ, et al. Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma. Biol Blood Marrow Transplant. 2014;20(3):402–408.e1. https://doi.org/10.1016/j.bbmt.2013.12.557.

    Article  PubMed  Google Scholar 

  27. El Fakih R, Fox P, Popat U, et al. Autologous hematopoietic stem cell transplantation in dialysis-dependent myeloma patients. Clin Lymphoma Myeloma Leuk. 2015;15(8):472–6. https://doi.org/10.1016/j.clml.2015.03.003.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Parikh GC, Amjad AI, Saliba RM, et al. Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma. Biol Blood Marrow Transplant. 2009;15(7):812–6. https://doi.org/10.1016/j.bbmt.2009.03.021.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Singhal S, Powles R, Sirohi B, et al. Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma. Bone Marrow Transplant. 2002;30:673–9.

    Article  CAS  PubMed  Google Scholar 

  30. Kumar S, Lacy MQ, Dispenzieri A, et al. High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. Bone Marrow Transplant. 2004;34:161–7.

    Article  CAS  PubMed  Google Scholar 

  31. Alexanian R, Weber D, Delasalle K, et al. Clinical outcomes with intensive therapy for patients with primary resistant multiple myeloma. Bone Marrow Transplant. 2004;34:229–34.

    Article  CAS  PubMed  Google Scholar 

  32. Rosinol L, Garcia-Sanz R, Lahuerta JJ, et al. Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease. Haematologica. 2012;97:616–21.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Vij R, Kumar S, Zhang MJ, et al. Impact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2015;21:335–41.

    Article  PubMed  Google Scholar 

  34. Kumar S, Giralt S, Stadtmauer EA, et al. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide, lenalidomide-, or bortezomib-containing regimens. Blood. 2009;114:1729–35.

    Article  CAS  PubMed  Google Scholar 

  35. Giralt S, Costa L, Schriber J, et al. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol Blood Marrow Transplant. 2014;20:295–308.

    Article  PubMed  Google Scholar 

  36. DiPersio JF, Stadtmauer EA, Nademanee A, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009;113(23):5720–6. https://doi.org/10.1182/blood-2008-08-174946.

    CAS  PubMed  Google Scholar 

  37. Kumar S, Giralt S, Stadtmauer EA. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood. 2009;114(9):1729–35. https://doi.org/10.1182/blood-2009-04-20501.

    Article  CAS  PubMed  Google Scholar 

  38. Moreau P, Facon T, Attal M, et al. Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood. 2002;99:731–5.

    Article  CAS  PubMed  Google Scholar 

  39. Lahuerta JJ, Mateos MV, Martinez-Lopez J, et al. Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as condition in regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study. Haematologica. 2010;95:1913–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Fenk R, Schneider P, Kropff M, et al. High-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma: results of a randomised study. Br J Haematol. 2005;130:588–94.

    Article  CAS  PubMed  Google Scholar 

  41. Lonial S, Kaufman J, Tighiouart M, et al. A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study. Clin Cancer Res. 2010;16:5079–86.

    Article  CAS  PubMed  Google Scholar 

  42. Sharma M, Khan H, Thall PF, et al. A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. Cancer. 2012;118:2507–15.

    Article  CAS  PubMed  Google Scholar 

  43. Sahebi F, Jacobelli S, Biezen AV, et al. Comparison of upfront tandem autologous–allogeneic transplantation versus reduced intensity allogeneic transplantation for multiple myeloma. Bone Marrow Transplant. 2015;50:802–7. https://doi.org/10.1038/bmt.2015.45; published online 23 March 2015.

    Article  CAS  PubMed  Google Scholar 

  44. Smith E, Devlin SM, Kosuri S, et al. cd34-selected allogeneic hematopoietic stem cell transplantation for patients with relapsed, high-risk multiple myeloma. Biol Blood Marrow Transplant. 2016;22(2):258–67. https://doi.org/10.1016/j.bbmt.2015.08.025.

    Article  PubMed  Google Scholar 

  45. Campagnaro E, Saliba R, Giralt S, et al. Symptom burden after autologous stem cell transplantation for multiple myeloma. Cancer. 2008;112:1617–24.

    Article  PubMed  Google Scholar 

  46. Wang XS, Giralt SA, Mendoza TR, et al. Clinical factors associated with cancer-related fatigue in patients being treated for leukemia and non-Hodgkin’s lymphoma. J Clin Oncol. 2002;20(5):1319–28.

    PubMed  Google Scholar 

  47. D’Souza A, Huang J, Fei M, Hari P. Trends in pre- and post-transplant therapies prior to first autologous hematopoietic cell transplantation among patients with multiple myeloma in the United States, 2004–2014. Blood. 2016; Abstract.

    Google Scholar 

  48. Jakubowiak AJ, et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood. 2012;120(9):1801–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Palumbo A, Cavallo F, Gay F, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 2014;371(10):895–905. https://doi.org/10.1056/ NEJMoa 1402888.

    Article  PubMed  Google Scholar 

  50. Gay F, Oliva S, Petrucci MT, et al. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Lancet Oncol. 2015;16(16):1617–29. https://doi.org/10.1016/S1470-2045(15)00389-7.

    Article  CAS  PubMed  Google Scholar 

  51. Attal M, Lauwers-Cances V, Hulin C, et al. Autologous transplantation for multiple myeloma in the era of new drugs: a Phase III Study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 trial). Blood. 2015;126:391.

    Google Scholar 

  52. Cavo M, Beksac M, Dimopoulos M, et al Intensification therapy with Bortezomib-Melphalan-Prednisone versus autologous stem cell transplantation for newly diagnosed multiple myeloma: an intergroup, multicenter, Phase III Study of the European Myeloma Network (EMN02/HO95 MM Trial). Blood. 2016; Abstract.

    Google Scholar 

  53. Attal M, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003;349(26):2495–502.

    Article  CAS  PubMed  Google Scholar 

  54. Cavo M, et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol. 2007;25(17):2434–4.

    Google Scholar 

  55. Salwender H, et al. Double vs. single autologous stem cell transplantation after Bortezomib-based induction regimens for multiple myeloma: an integrated analysis of patient-level data from Phase European III studies. Blood. 2013;122(21):767.

    Google Scholar 

  56. Cavo M, Petrucci MT, Di Raimondi F, et al. Upfront single versus double autologous stem cell transplantation for newly diagnosed multiple myeloma: an intergroup, multicenter, Phase III study of the European Myeloma Network (EMN02/HO95 MM trial). Blood. 2016;128:991.

    Google Scholar 

  57. Stadtmauer E, Pasquini M, Blackwell B, et al. Comparison of autologous hematopoietic cell transplant (autoHCT), bortezomib, lenalidomide (Len) and dexamethasone (RVD) consolidation with len maintenance (ACM), tandem autohct with len maintenance (TAM) and autohct with len maintenance (AM) for up-front treatment of patients with multiple myeloma (MM): primary results from the randomized Phase III trial of the blood and marrow transplant clinical trials network (BMT CTN 0702—StaMINA trial) Blood. 2016;128.

    Google Scholar 

  58. Gahrton G, et al. Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. Blood. 2013;121(25):5055–63.

    Article  CAS  PubMed  Google Scholar 

  59. Krishnan A, Pasquini M, Logan B, et al. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol. 2011;12(13):1195–203.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Lokhorst HM, et al. Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study. Blood. 2012;119(26):6219–25.

    Article  CAS  PubMed  Google Scholar 

  61. Bruno B, Rotta M, Patriarca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med. 2007;356(11):1110–20.

    Article  CAS  PubMed  Google Scholar 

  62. Kumar S, et al. Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis. Blood. 2011;118(7):1979–88.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Giralt S, Garderet L, Durie B, et al. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on salvage hematopoietic cell transplantation in patients with relapsed multiple myeloma. Biol Blood Marrow Transplant. 2015;21:2039–51.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Cook G, Williams C, Brown JM, et al. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [intensive trial]): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:874–85.

    Article  CAS  PubMed  Google Scholar 

  65. Freytes CO, Vesole DH, LeRademacher L, et al. Second transplants for multiple myeloma relapsing after a previous autotransplant-reduced intensity allogeneic versus autologous transplantation. Bone Marrow Transplant. 2014;49:416–21.

    Article  CAS  PubMed  Google Scholar 

  66. Patriarca F, Einsele H, Spina F, et al. Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability. Biol Blood Marrow Transplant. 2012;18:617–26.

    Article  CAS  PubMed  Google Scholar 

  67. De Lavallade H, El-Cheikh J, Faucher C, et al. Reduced-intensity conditioning allogeneic SCT as a salvage treatment for relapsed multiple myeloma. Bone Marrow Transplant. 2008;41:953–60.

    Article  PubMed  Google Scholar 

  68. Ladetto M, et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol. 2010;28(12):2077–84.

    Article  CAS  PubMed  Google Scholar 

  69. Cavo M, et al. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood. 2012;120(1):9–19.

    Article  CAS  PubMed  Google Scholar 

  70. Mellqvist UH, et al. Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. Blood. 2013;121(23):4647–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. McCarthy P, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1770–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1782–91.

    Article  CAS  PubMed  Google Scholar 

  73. Palumbo A, Cavallo F, Gay F, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 2014;371:895–905. https://doi.org/10.1056/NEJMoa1402888.

    Article  PubMed  Google Scholar 

  74. Attal M, Palumbo A, Holstein SA, et al. Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): A meta-analysis (MA) of overall survival (OS). J Clin Oncol. 2016;34 (suppl; abstr 8001).

    Google Scholar 

  75. Chanan Khan A, Giralt S. Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol. 2010;28(15):2612–24. https://doi.org/10.1200/JCO.2009.25.4250.

    Article  CAS  PubMed  Google Scholar 

  76. Lahuerta JJ, et al. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol. 2008;26(35):5775–82.

    Article  PubMed  Google Scholar 

  77. Mailankody S, Korde N, Lesokhin AM, et al. Minimal residual disease in multiple myeloma: bringing the bench to the bedside. Nat Rev Clin Oncol. 2015;12(5):286–95. https://doi.org/10.1038/nrclinonc.2014.239. Review

    Article  PubMed  Google Scholar 

  78. Garfall AL, Stadtmauer EA. Cellular and vaccine immunotherapy for multiple myeloma. Hematology Am Soc Hemtol Educ Program. 2016;2016(1):521–7.

    Google Scholar 

  79. Rosenblatt J, Avigan D Targeting the PD-1/PD-L1 axis in multiple myeloma: a dream or a reality. Blood. 2016. pii: blood-2016-08-731885 [Epub ahead of print].

    Google Scholar 

  80. Chung DJ, Pronschinske KB, Shyer JA, et al. T-cell exhaustion in multiple myeloma relapse after autotransplant: optimal timing of immunotherapy. Cancer Immunol Res. 2016;4:61–71.

    Article  CAS  PubMed  Google Scholar 

  81. Appelbaum FR, Anasetti C, Antin JH, et al. Blood and marrow transplant clinical trials network state of the Science Symposium 2014. Biol Blood Marrow Transplant. 2015;21(2):202–24. https://doi.org/10.1016/j.bbmt.2014.10.003.

    Article  PubMed  Google Scholar 

  82. Landgren O, Giralt S. MRD-driven treatment paradigm for newly diagnosed transplant eligible multiple myeloma patients. Bone Marrow Transplant. 2016;51(7):913–4. https://doi.org/10.1038/bmt.2016.24.

    Article  CAS  PubMed  Google Scholar 

  83. Dispenzieri A. Myeloma: management of the newly diagnosed high risk patient. Hematology Am Soc Hemtol Educ Program. 2016;1:485–94.

    Google Scholar 

  84. Moreau P, Chanan-Khan A, Roberts AW, et al. Venetoclax combined with bortezomib and dexamethasone for patients with relapsed/refractory multiple myeloma. Blood. 2016;128:975.

    Google Scholar 

  85. Zimmerman T, Raje NS, Vij R, et al. Final results of a Phase 2 trial of extended treatment (tx) with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (KRd) plus autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (NDMM). Blood. 2016; Abstract 675.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adult BMT Service, Memorial Sloan Kettering Cancer Center, New York City, NY, USA

    Heather Landau M.D.

  2. Chief, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Sergio Giralt M.D.

Authors
  1. Heather Landau M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sergio Giralt M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sergio Giralt M.D. .

Editor information

Editors and Affiliations

  1. Cancer Research Foundation, Chappaqua, New York, USA

    Peter H. Wiernik

  2. Cancer Research Foundation, Chappaqua, New York, USA

    Janice P. Dutcher

  3. Department of Hematology, Mayo Clinic Department of Hematology, Rochester, Minnesota, USA

    Morie A. Gertz

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Cite this chapter

Landau, H., Giralt, S. (2018). Role of Hematopoietic Cell Transplantation for Myeloma. In: Wiernik, P., Dutcher, J., Gertz, M. (eds) Neoplastic Diseases of the Blood. Springer, Cham. https://doi.org/10.1007/978-3-319-64263-5_29

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-64263-5_29

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-64262-8

  • Online ISBN: 978-3-319-64263-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation